BSX
Boston Scientific Corporation NYSE Listed May 19, 1992$56.57
After hrs
$54.00
+0.13%
Mkt Cap $84.1B
52w Low $54.98
2.9% of range
52w High $109.50
50d MA $65.84
200d MA $89.28
P/E (TTM)
28.8x
EV/EBITDA
40.6x
P/B
3.4x
Debt/Equity
0.5x
ROE
11.9%
P/FCF
38.6x
RSI (14)
—
ATR (14)
—
Beta
0.78
50d MA
$65.84
200d MA
$89.28
Avg Volume
19.1M
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
300 Boston Scientific Way · Marlborough, MA 01752-1234 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | AMC | 0.79 | 0.80 | +1.5% | 64.87 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% | — |
| Feb 4, 2026 | AMC | 0.78 | 0.80 | +2.4% | 75.50 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% | — |
| Oct 22, 2025 | AMC | 0.71 | 0.75 | +5.0% | 103.85 | +0.4% | -1.4% | -2.6% | -1.4% | -2.8% | -3.4% | — |
| Jul 23, 2025 | AMC | 0.72 | 0.75 | +3.4% | 107.76 | +0.5% | -1.4% | -1.5% | -1.8% | -1.2% | -0.9% | — |
| Apr 23, 2025 | AMC | 0.67 | 0.75 | +11.4% | 98.87 | +0.2% | +2.3% | +3.1% | +3.3% | +3.9% | +4.0% | — |
| Feb 5, 2025 | AMC | 0.66 | 0.70 | +6.5% | 104.97 | +0.7% | +0.0% | +0.3% | +1.2% | +1.0% | +0.8% | — |
| Oct 23, 2024 | AMC | 0.59 | 0.63 | +7.1% | 87.45 | +1.1% | -2.7% | -3.1% | -3.1% | -3.3% | -4.0% | — |
| Jul 24, 2024 | AMC | 0.58 | 0.62 | +6.3% | 77.76 | +0.6% | -4.5% | -3.7% | -2.8% | -4.8% | -5.0% | — |
| Apr 24, 2024 | AMC | 0.51 | 0.56 | +8.9% | 72.91 | +0.3% | +0.5% | +0.4% | -0.6% | -1.4% | -1.0% | — |
| Jan 31, 2024 | AMC | 0.51 | 0.55 | +7.8% | 63.26 | +1.9% | +2.5% | +1.8% | +1.9% | +2.4% | +3.1% | — |
| Oct 26, 2023 | AMC | 0.48 | 0.50 | +4.2% | 49.78 | +1.0% | -0.5% | +0.5% | +2.8% | +3.8% | +5.5% | — |
| Jul 27, 2023 | AMC | 0.49 | 0.53 | +8.2% | 52.64 | +0.8% | -1.8% | -1.5% | -1.4% | -3.8% | -3.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | RBC Capital | Maintains | Outperform → Outperform | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Baird | Maintains | Outperform → Outperform | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Truist | Maintains | Buy → Buy | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Barclays | Maintains | Overweight → Overweight | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Needham | Maintains | Buy → Buy | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Goldman Sachs | Maintains | Buy → Buy | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 22 | Jefferies | Maintains | Buy → Buy | — | $59.52 | $62.51 | +5.0% | +9.0% | +10.4% | +4.3% | +0.7% | -1.8% |
| Apr 22 | BTIG | Maintains | Buy → Buy | — | $59.52 | $62.51 | +5.0% | +9.0% | +10.4% | +4.3% | +0.7% | -1.8% |
| Apr 22 | Barclays | Maintains | Overweight → Overweight | — | $59.52 | $62.51 | +5.0% | +9.0% | +10.4% | +4.3% | +0.7% | -1.8% |
| Apr 21 | Stifel | Maintains | Buy → Buy | — | $60.99 | $60.74 | -0.4% | -2.4% | +6.4% | +7.7% | +1.8% | -1.7% |
| Apr 15 | Truist | Maintains | Buy → Buy | — | $63.82 | $64.04 | +0.3% | +1.2% | -0.6% | +0.6% | -4.4% | -6.7% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $61.79 | $61.50 | -0.5% | +2.2% | +3.3% | +4.6% | +2.6% | +3.9% |
| Apr 7 | Citigroup | Maintains | Buy → Buy | — | $62.59 | $62.15 | -0.7% | -1.2% | -0.0% | -2.1% | -1.3% | +0.9% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $62.82 | $62.32 | -0.8% | -0.4% | -1.5% | -0.4% | -2.5% | -1.6% |
| Mar 30 | Needham | Maintains | Buy → Buy | — | $69.17 | $64.20 | -7.2% | -9.0% | -9.3% | -10.4% | -9.2% | -9.5% |
| Mar 30 | RBC Capital | Maintains | Outperform → Outperform | — | $69.17 | $64.20 | -7.2% | -9.0% | -9.3% | -10.4% | -9.2% | -9.5% |
| Mar 30 | Raymond James | Downgrade | Strong Buy → Outperform | — | $69.17 | $64.20 | -7.2% | -9.0% | -9.3% | -10.4% | -9.2% | -9.5% |
| Mar 27 | Goldman Sachs | Maintains | Buy → Buy | — | $70.17 | $70.03 | -0.2% | -1.4% | -10.3% | -10.6% | -11.6% | -10.5% |
| Mar 20 | Needham | Maintains | Buy → Buy | — | $69.89 | $69.77 | -0.2% | -0.6% | -0.5% | -2.5% | -0.2% | +0.4% |
| Mar 20 | Stifel | Maintains | Buy → Buy | — | $69.89 | $69.77 | -0.2% | -0.6% | -0.5% | -2.5% | -0.2% | +0.4% |
| Mar 18 | Truist | Maintains | Buy → Buy | — | $71.20 | $70.73 | -0.7% | +0.1% | -1.8% | -2.4% | -2.3% | -4.3% |
| Mar 17 | UBS | Maintains | Buy → Buy | — | $69.79 | $70.13 | +0.5% | +2.0% | +2.1% | +0.1% | -0.4% | -0.4% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $69.96 | $70.14 | +0.3% | -0.5% | -2.0% | -1.2% | -0.2% | +1.8% |
| Feb 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $74.73 | $75.03 | +0.4% | +2.1% | +2.1% | +1.3% | -0.2% | -0.5% |
| Feb 9 | BTIG | Maintains | Buy → Buy | — | $76.27 | $75.61 | -0.9% | -2.8% | -2.6% | -3.7% | -2.8% | -2.0% |
| Feb 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | JP Morgan | Maintains | Overweight → Overweight | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Truist | Maintains | Buy → Buy | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Mizuho | Maintains | Outperform → Outperform | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Evercore ISI | Maintains | Outperform → Outperform | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Stifel | Maintains | Buy → Buy | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Needham | Maintains | Buy → Buy | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | TD Cowen | Maintains | Buy → Buy | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Baird | Maintains | Outperform → Outperform | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Citigroup | Maintains | Buy → Buy | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | UBS | Maintains | Buy → Buy | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | RBC Capital | Maintains | Outperform → Outperform | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $75.50 | $77.35 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% |
| Feb 4 | BTIG | Maintains | Buy → Buy | — | $91.62 | $81.38 | -11.2% | -17.6% | -15.3% | -16.8% | -19.1% | -19.0% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $91.87 | $91.54 | -0.4% | -0.3% | -17.8% | -15.5% | -17.0% | -19.3% |
| Jan 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $90.03 | $90.02 | -0.0% | -2.2% | +1.3% | +1.9% | +1.4% | +2.8% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $94.48 | $95.00 | +0.6% | +1.7% | +1.2% | +2.1% | +1.7% | +1.7% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $92.95 | $93.77 | +0.9% | +1.6% | +3.4% | +2.9% | +3.7% | +3.4% |
| Dec 17 | RBC Capital | Maintains | Outperform → Outperform | — | $92.95 | $93.77 | +0.9% | +1.6% | +3.4% | +2.9% | +3.7% | +3.4% |
| Nov 21 | BTIG | Maintains | Buy → Buy | — | $96.60 | $96.45 | -0.2% | +0.3% | +1.5% | +4.9% | +4.5% | +5.2% |
| Oct 23 | Truist | Maintains | Buy → Buy | — | $103.85 | $104.29 | +0.4% | -1.4% | -2.6% | -1.4% | -2.8% | -3.4% |
No insider trades available.
8-K
Boston Scientific Corp. -- 8-K Filing
Boston Scientific delivered strong Q1 2026 results with 11.6% reported sales growth to $5.2 billion and doubled net income to $1.341 billion, signaling robust operational momentum for shareholders.
Apr 22
8-K · 5.02
!!! Very High
Envoy Medical, Inc. -- 8-K 5.02: Executive Change
Charles S. McKhann joined Envoy Medical's board as a Class I director, potentially bringing new expertise and perspective to the company's governance and strategic direction.
Apr 21
S-4
!!! Very High
Unknown — Merger Registration
BSX shareholders are receiving $374 cash per share in a merger, providing immediate liquidity but eliminating future upside potential from the combined entity.
Mar 30
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Boston Scientific's EKOS system achieved superior clinical outcomes in a major PE treatment trial, potentially expanding its addressable market and supporting premium pricing for this interventional device.
Mar 30
8-K
Unknown — 8-K Filing
ELUT's NXT-41 FDA submission positions the company for potential 2026-2027 clearances, but limited cash ($44.4M) raises dilution concerns for investors awaiting clinical validation and regulatory milestones.
Mar 11
S-4
!!! Very High
Boston Scientific Corp. -- Merger Registration
Boston Scientific completed a merger with approximately $374 million in cash reserves, indicating the company retained substantial liquidity for post-combination operations and strategic investments.
Feb 27
8-K · 1.01
! Medium
Boston Scientific Corp. -- 8-K 1.01: Financing / Debt Agreement
Boston Scientific secured a $3 billion revolving credit facility with Wells Fargo, providing flexible liquidity for operational and strategic needs.
Feb 26
8-K · 5.02
!!! Very High
Boston Scientific Corp. -- 8-K 5.02: Executive Change
Boston Scientific appointed Catherine R. Smith and Christophe P. Weber as directors effective February 18, 2026, strengthening board composition with new independent oversight.
Feb 23
8-K · 5.02
!!! Very High
Boston Scientific Corp. -- 8-K 5.02: Executive Change
Yoshiaki Fujimori's decision not to seek re-election at Boston Scientific reduces board continuity, potentially signaling leadership transition or strategic shifts within the company's governance structure.
Feb 5
8-K
Boston Scientific Corp. -- 8-K Filing
Boston Scientific reported fourth-quarter 2025 net sales of $5.286 billion, achieving 15.9% reported growth driven by strong operational and organic expansion across its business.
Feb 4
Data updated apr 24, 2026 10:59pm
· Source: massive.com